19:24 , Jun 1, 2018 |  BC Week In Review  |  Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) raised $152.6 million on May 23 through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush. Kiniksa priced...
04:13 , May 24, 2018 |  BC Extra  |  Financial News

Kiniksa upsizes IPO, raises $152.6M

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) gained $1.47 to $19.47 Thursday after raising $152.6 million through the sale of 8.5 million shares at $18 in an upsized IPO underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and...
02:32 , May 18, 2018 |  BC Week In Review  |  Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on May 14 for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to...
22:58 , May 14, 2018 |  BC Extra  |  Financial News

Kiniksa, Scholar Rock set IPO price ranges

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) and Scholar Rock Holding Corp. (Cambridge, Mass.) each set price ranges on Monday for their respective NASDAQ IPOs. Kiniksa now plans to sell 7 million shares at $17 to $19...
16:04 , May 4, 2018 |  BC Week In Review  |  Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed on April 27 to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO...
22:02 , Apr 28, 2018 |  BC Extra  |  Financial News

Ex-Synageva team planning Kiniksa IPO

Kiniksa Pharmaceuticals Ltd. (Hamilton, Bermuda) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, JMP Securities and Wedbush PacGrow. Kiniksa Chairman and CEO Sanj Patel, President...
00:08 , Dec 2, 2017 |  BioCentury  |  Strategy

Branching out

Decibel Therapeutics Inc. and Regeneron Pharmaceuticals Inc. have embarked on a deal that gives the smaller company a suite of technologies it could not build itself, while giving the big cap a stake in a...
01:29 , Apr 15, 2017 |  BioCentury  |  Strategy

WAC-a-mol

While investors, media and even some payers have been touting the pricing of three recently launched drugs as sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But...
22:23 , Apr 6, 2017 |  BC Innovations  |  Targets & Mechanisms

Competing for growth

With little in the clinical pipeline for achondroplasia beyond BioMarin Pharmaceutical Inc. ’s late-stage vosoritide, startups Therachon AG and BioClin Therapeutics Inc. are rethinking how to tackle the disease. By targeting FGFR3 directly, the two...
07:00 , Sep 19, 2016 |  BC Week In Review  |  Company News

Regeneron, Neovii Pharmaceuticals deal

Regeneron granted Neovii worldwide rights, except in the U.S. and Japan, to develop and commercialize Arcalyst rilonacept to treat periodic fever syndromes. The company said it will focus initially on familial Mediterranean fever. The recombinant...